Data show that metformin can reverse PARPi-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer by sensitizing PARPi-resistant cells to cytotoxic T cells [87]. This evidence concerns the gene CD274 and triple-negative breast carcinoma.